GL261-luc Orthotopic Mouse Model Service for Brain Cancer

The GL261-luc orthotopic mouse model stands as the most widely utilized syngeneic glioblastoma platform, enabling real-time bioluminescence tracking of tumor growth and treatment response within the fully immunocompetent central nervous system of C57BL/6 mice. Alfa Cytology constructs, validates, and manages this luciferase-reporter glioma system with integrated imaging and neuropathological endpoints, delivering reproducible preclinical data to advance neuro-oncology discovery programs from target validation through candidate selection.

Overview of GL261-luc Orthotopic Mouse Model for Brain Cancer

The GL261-luc orthotopic model is generated by stereotactically implanting luciferase-transduced GL261 murine glioma cells into the striatum of syngeneic C57BL/6 mice, producing an intracranial tumor that recapitulates the aggressive growth, pseudopalisading necrosis, and florid angiogenesis characteristic of human glioblastoma. Originally induced by 3-methylcholanthrene carcinogenesis, the GL261 line harbors K-Ras and Trp53 driver mutations alongside elevated c-Myc expression, conferring a transcriptional profile enriched in interferon signaling pathways that distinguishes it from other chemically induced murine glioma models. The stable integration of firefly luciferase permits non-invasive, longitudinal bioluminescence imaging of tumor burden deep within the brain parenchyma, providing a quantitative surrogate for intracranial disease progression and therapeutic response without serial magnetic resonance imaging or repeated terminal sampling.

Fig 1. GL261 Red-FLuc vs TRP-mCherry-FLuc MRI. (Rodgers, L. T., et al., 2024)

Histologically, GL261-luc tumors display features of high-grade glioma with elevated mitotic activity, dense cellularity, nuclear polymorphism, and prominent microvascular proliferation accompanied by hemorrhagic infiltration into surrounding brain tissue. The model is distinguished by its moderate immunogenic profile, including baseline expression of MHC class I molecules and PD-L1 on tumor cells, which enables meaningful interrogation of immune checkpoint inhibitors, tumor vaccine strategies, and combination radio-immunotherapy regimens in a setting where innate and adaptive immune responses remain fully intact. Additionally, GL261 retains sensitivity to temozolomide and ionizing radiation, making it an indispensable substrate for evaluating standard-of-care combination protocols alongside novel experimental therapeutics in preclinical neuro-oncology.

Cell Line Information: GL261-luc

GL261-luc is a luciferase-reporter derivative of the GL261 murine glioblastoma cell line, generated through lentiviral transduction to stably express firefly luciferase for in vivo bioluminescent tracking. The parental GL261 line was originally induced by intracranial injection of 3-methylcholanthrene into C57BL/6 mice and subsequently maintained by serial syngeneic transplantation before establishment as a permanent in vitro cell culture. Key attributes are summarized below:

Our Services

Alfa Cytology offers end-to-end GL261-luc orthotopic glioma model services encompassing stereotactic surgical implantation, longitudinal bioluminescence imaging, small-animal MRI integration, and comprehensive neuropathological endpoint analysis. Every study is executed within fully accredited vivarium facilities under IACUC oversight, ensuring scientific rigor, ethical compliance, and complete data traceability from model construction through final report delivery.

Workflow of GL261-luc Orthotopic Mouse Model Construction

Construction of the GL261-luc orthotopic glioma model employs precision stereotactic intracranial injection to deliver tumor cells into the murine striatum, ensuring reproducible engraftment, minimal surgical morbidity, and consistent growth kinetics suitable for longitudinal therapeutic studies. The protocol integrates pre-operative analgesia, aseptic stereotactic surgery, controlled cell infusion, and bioluminescence monitoring, as detailed below:

1. Cell Preparation and Batch Validation: GL261-luc cells are expanded under low-passage conditions (passage 3–8) in complete medium to preserve tumorigenic potential and interferon-signaling phenotype. Viability is confirmed by trypan blue exclusion (>95% required), and luciferase expression is validated via in vitro bioluminescence assay to ensure uniform reporter signal intensity across the batch.
2. Animal Selection and Acclimation: Female C57BL/6 mice (8–10 weeks old) are selected to maintain syngeneic compatibility and preserve intact tumor–immune interactions. A one-week acclimation period is observed under specific-pathogen-free housing, with daily health monitoring and body weight recording to establish individual baseline parameters.
3. Pre-Operative Analgesia and Anesthesia: Mice receive pre-operative analgesia comprising buprenorphine (0.1 mg/kg) and carprofen (5 mg/kg) subcutaneously. General anesthesia is induced and maintained with isoflurane (3% induction, 1.5–2% maintenance) delivered via nose cone, with continuous respiration and body temperature monitoring throughout the procedure.
4. Surgical Site Preparation: The scalp is shaved and depilatory cream is applied to remove fur, followed by sterilization with iodine solution. The mouse is secured in a stereotaxic frame with ear bars and a bite bar, and a single midline incision is made to expose the skull surface and identify the bregma landmark.
5. Craniotomy and Dural Exposure: A small burr hole is drilled at the predetermined stereotactic coordinates (anteroposterior +1 mm, mediolateral +2 mm relative to bregma) using a high-speed microdrill under constant saline cooling. The dura mater is carefully pierced to expose the underlying parenchyma without causing cortical trauma or hemorrhage.
6. Tumor Cell Injection: A 10 µL Hamilton syringe fitted with a glass micropipette is lowered through the burr hole to a depth of −3 mm relative to bregma, targeting the right striatum. GL261-luc cells (1 × 10⁵) in 2 µL PBS are delivered using a micropump injector over 2 minutes at a constant infusion rate. A single-cell suspension is essential to prevent clumping and ensure uniform tumor seeding within the striatal parenchyma.
7. Needle Retraction and Wound Closure: The needle is left in place for an additional 2 minutes to prevent retrograde flow along the injection tract, then withdrawn slowly over 1 minute to minimize cell tracking. The scalp incision is closed with surgical sutures or tissue adhesive, and the mouse is transferred to a heated recovery chamber.
8. Post-Operative Care and Monitoring: Mice receive carprofen-supplemented drinking water (33 µg/mL) for 72 hours post-surgery and are monitored twice daily for neurological deficits, body weight, and wound integrity. Animals are allowed to recover for a minimum of 3 days before initiation of any imaging or treatment protocol.
9. Bioluminescence Imaging and Tumor Monitoring: Starting at day 3–7 post-implantation, tumor establishment and growth are monitored via IVIS Spectrum or equivalent bioluminescence imaging system following intraperitoneal D-luciferin administration (150 mg/kg). Regions of interest are drawn over the cranial vault, and photon flux (photons/sec/cm²/sr) is quantified to generate longitudinal growth curves for each animal.
10. Endpoint Analysis and Neuropathology: At study termination, mice are humanely euthanized and brains are excised, weighed, and processed for formalin-fixed paraffin embedding. Coronal serial sections are stained with H&E for morphological assessment, and immunohistochemistry is performed for Ki67, CD31, GFAP, Iba1, and PD-L1 to confirm tumor origin, proliferative index, vascular density, microglial activation, and immune checkpoint expression.

Fig 2. GL261-luc Orthotopic Mouse Model construction workflow.

Case Study-GL261-luc Orthotopic Mouse Model Development

In a representative preclinical program, the GL261-luc orthotopic model was deployed to evaluate the efficacy of a combinatorial regimen integrating focal radiotherapy with an investigational immune checkpoint inhibitor in glioblastoma. Following stereotactic implantation and confirmation of engraftment by bioluminescence imaging within the first week, cohorts were randomized to receive either the combination therapy, monotherapy arms, or vehicle control. Longitudinal BLI revealed distinct growth trajectories across treatment groups, with the combination cohort demonstrating attenuated photon flux accumulation relative to both monotherapy and control arms. Terminal neuropathological analysis showed reduced intracranial tumor burden, diminished microvascular proliferation, and elevated CD8+ T-cell infiltration in the combination group, alongside preserved peritumoral brain architecture in responders. These preclinical findings informed the regimen's mechanism-of-action hypothesis and supported advancement toward subsequent pharmacology and toxicology studies.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your GL261-luc orthotopic glioma program provides access to a neuroscience-focused, quality-driven preclinical infrastructure optimized for intracranial tumor research and immuno-oncology evaluation. Our core differentiators include:

• Extensive experience with syngeneic glioma model development, with optimized stereotactic surgical protocols that achieve consistent striatal engraftment and predictable tumor kinetics in immunocompetent C57BL/6 hosts.
• Integrated bioluminescence and small-animal MRI imaging platforms enabling non-invasive, quantitative longitudinal tracking of intracranial tumor dynamics without introducing serial sacrifice artifacts into your dataset.
• Rigorous cell banking and authentication procedures, encompassing mycoplasma screening, luciferase expression validation, and short tandem repeat profiling to ensure model fidelity and experimental reproducibility.
• Adaptable study architectures supporting single-agent screening, combination radio-immunotherapy regimens, checkpoint inhibitor evaluation, tumor vaccine assessment, and pharmacodynamic biomarker analysis tailored to your therapeutic modality.
• Comprehensive neuropathological endpoint capabilities including digital histopathology, immunohistochemistry for vascular and immune markers, multiplex immunofluorescence, and flow cytometry of tumor-infiltrating leukocytes.
• A dedicated scientific project management team providing transparent milestone reporting, timeline accountability, and direct consultation from protocol design through final data package delivery.

Contact Us

Whether your program targets glioblastoma with a novel immune checkpoint inhibitor, a tumor vaccine approach, a temozolomide combination strategy, or a blood-brain barrier-penetrant agent, Alfa Cytology is equipped to accelerate your preclinical development with our GL261-luc orthotopic glioma expertise. Reach out to us today to discuss your study design, review our imaging and surgical capabilities, and receive a customized proposal aligned with your scientific objectives and timeline. Our neuro-oncology team looks forward to collaborating with you to generate the robust, translationally relevant data your pipeline demands.

For research use only. Not intended for any clinical use.